Genetic liabilities differentiating bipolar disorder, schizophrenia and major depression and phenotypic heterogeneity in bipolar disorder

Richards, Alexander, Cardno, Alastair, Harold, Gordon, Craddock, Nicholas ORCID: https://orcid.org/0000-0003-2171-0610, Di Florio, Arianna ORCID: https://orcid.org/0000-0003-0338-2748, Jones, Lisa ORCID: https://orcid.org/0000-0001-5821-5889, Gordon-Smith, Katherine, Jones, Ian ORCID: https://orcid.org/0000-0001-5821-5889, Sellers, Ruth, Walters, James ORCID: https://orcid.org/0000-0002-6980-4053, Holmans, Peter, Owen, Michael J. ORCID: https://orcid.org/0000-0003-4798-0862 and O'Donovan, Michael ORCID: https://orcid.org/0000-0001-7073-2379 2022. Genetic liabilities differentiating bipolar disorder, schizophrenia and major depression and phenotypic heterogeneity in bipolar disorder. JAMA Psychiatry 79 (10) , pp. 1032-1039. 10.1001/jamapsychiatry.2022.2594

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (299kB) | Preview

Abstract

Importance: Understanding the origins of clinical heterogeneity in bipolar disorder (BD) will inform new approaches to stratification and studies of underlying mechanisms. Objective: To identify components of genetic liability that are shared between BD, schizophrenia, and major depressive disorder (MDD) and those that differentiate each disorder from the others and to examine associations between heterogeneity for key BD symptoms and each component. Design, setting, and participants: Using data from the Bipolar Disorder Research Network in the United Kingdom, components of liability were identified by applying genomic structural equation modeling to genome-wide association studies of schizophrenia, BD, and MDD. Polygenic risk scores (PRS) representing each component were tested for association with symptoms in an independent BD data set. Adults with DSM-IV BD or schizoaffective disorder, bipolar type, were included. Data were collected from January 2000 to December 2013, and data were analyzed from June 2020 to February 2022. Main outcomes and measures: PRS representing the components of liability were tested for association with mania and depression, psychosis, and mood incongruence of psychosis in participants with BD, measured using the Bipolar Affective Disorder Dimensional Scale. Results: Of 4429 included participants, 3012 (68.0%) were female, and the mean (SD) age was 46.2 (12.3) years. Mania and psychosis were associated with the shared liability component (mania β = 0.29; 95% CI, 0.23-0.34; P = 3.04 × 10-25; psychosis β = 0.05; 95% CI, 0.04-0.07; P = 2.33 × 10-13) and the components that differentiate each of schizophrenia (mania β = 0.08; 95% CI, 0.03-0.14; P = .002; psychosis β = 0.03; 95% CI, 0.01-0.04; P = 1.0 × 10-4) and BD (mania β = 0.14; 95% CI, 0.09-0.20; P = 1.99 × 10-7; psychosis β = 0.02; 95% CI, 0.01-0.03; P = .006) from the other disorders. The BD differentiating component was associated with mania independently of effects on psychosis (β = 0.14; 95% CI, 0.08-0.20; P = 4.32 × 10-6) but not with psychosis independently of mania. Conversely, the schizophrenia differentiating component was associated with psychosis independently of effects on mania (β = 0.01; 95% CI, 0.003-0.03; P = .02), but not with mania independently of psychosis. Mood incongruence of psychosis was associated only with the schizophrenia differentiating component (β = 0.03; 95% CI, 0.01-0.05; P = .005). Depression was associated with higher MDD differentiating component (β = 0.07; 95% CI, 0.01-0.12; P = .01) but lower BD differentiating component (β = -0.11; 95% CI, -0.17 to -0.06; P = 7.06 × 10-5). Conclusions and relevance: In this study of BD, clinical heterogeneity reflected the burden of liability to BD and the contribution of alleles that have differentiating effects on risk for other disorders; mania, psychosis, and depression were associated with the components of genetic liability differentiating BD, MDD, and schizophrenia, respectively. Understanding the basis of this etiological heterogeneity will be critical for identifying the different pathophysiological processes underlying BD, stratifying patients, and developing precision therapeutics.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	American Medical Association
ISSN:	2168-622X
Date of First Compliant Deposit:	15 July 2022
Date of Acceptance:	11 July 2022
Last Modified:	10 Oct 2023 23:35
URI:	https://orca.cardiff.ac.uk/id/eprint/151318

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item